乌美溴铵/维兰特罗
 乌美溴铵（上方）和维兰特罗（下方） | |
| 组成 | |
|---|---|
| 乌美溴铵 | 毒蕈碱拮抗剂 |
| 维兰特罗 | 超长效β2激动剂 |
| 臨床資料 | |
| 商品名 | Anoro Ellipta、Laventair Ellipta |
| AHFS/Drugs.com | 专业药物信息 |
| 核准狀況 | |
| 懷孕分級 |
|
| 给药途径 | 吸入给药 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 2446159-58-4 |
| KEGG | |
乌美溴铵/维兰特罗（英语：umeclidinium bromide/vilanterol；商品名：Anoro Ellipta等），是一种用于治疗慢性阻塞性肺病 (COPD) 的固定剂量复方药物。[4][5]它通过吸入给药。
最常见的副作用包括上呼吸道感染、尿路感染、咽炎、鼻窦炎、鼻咽炎、头痛、咳嗽、口咽疼痛、便秘和口干。[3]
2021年，它是美国第212位最常用处方药物，处方数量超过200万张。[6][7]
参考资料[编辑]
- ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].
- ^ Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC). (emc). 7 October 2019 [29 October 2020].
- ^ 3.0 3.1 Anoro Ellipta EPAR. European Medicines Agency (EMA). 17 September 2018 [28 October 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. December 2013, 7 (6): 311–9. PMID 24004659. S2CID 5744282. doi:10.1177/1753465813499789.
- ^ FDA Approves Umeclidinium and Vilanterol Combo for COPD. Medscape. 18 December 2013.
- ^ The Top 300 of 2021. ClinCalc. [14 January 2024]. （原始内容存档于15 January 2024）.
- ^ Umeclidinium; Vilanterol - Drug Usage Statistics. ClinCalc. [14 January 2024].
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 | 这是一篇關於呼吸系統的藥理學小作品。你可以通过编辑或修订扩充其内容。 |